EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial

Pediatric Allergy and Immunology - Tập 29 Số 8 - Trang 834-840 - 2018
Abbas Taghavi Ardakani1,2, Maryam Farrehi1,2, Mohammad Reza Sharif1,2, Vahidreza Ostadmohammadi2,3, Naghmeh Mirhosseini4, Davood Kheirkhah1,2, Gholam Abbas Moosavi5, Milad Behnejad3, Rüssel J. Reiter6, Zatollah Asemi3
1Department of Pediatrics, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
2Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran
3Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran
4Pure North S'Energy Foundation, Calgary, Alberta, Canada
5Department of Statistics and Public Health, Faculty of Health, Kashan University of Medical Sciences, Kashan, Iran
6Department of Cellular and Structural Biology, UT Health Science Center, San Antonio, TX, USA

Tóm tắt

AbstractBackgroundThe aim of this clinical trial was to determine the effects of melatonin administration on disease severity and sleep quality in children diagnosed with atopic dermatitis (AD).MethodsThis randomized, double‐blinded, placebo‐controlled trial was conducted by recruiting 70 patients, aged 6‐12 years, who had been diagnosed with AD. Study participants were randomly allocated into two intervention groups to receive either 6 mg/d melatonin supplements or placebo (n = 35 each group) for 6 weeks. Severity of disease was assessed using the scoring atopic dermatitis (SCORAD) and objective SCORAD indices. Sleep quality was evaluated by completing the Children's Sleep Habits Questionnaire (CSHQ).ResultsFollowing 6 weeks of intervention, melatonin supplementation significantly improved SCORAD index (β −3.55; 95% CI, −6.11, −0.98; P = 0.007), objective SCORAD index (β −3.23; 95% CI, −5.08, −1.38; P = 0.001), serum total IgE levels (β −153.94 ku/L; 95% CI, −260.39, −47.49; P = 0.005), and CSHQ scores (β −2.55; 95% CI, −4.34, −0.75; P = 0.006). However, melatonin had no significant impact on pruritus scores, high‐sensitivity C‐reactive protein (hs‐CRP), sleep‐onset latency, total sleep time, weight, and BMI compared with placebo.ConclusionsOverall, melatonin supplementation had beneficial effects on disease severity, serum total IgE levels, and CSHQ among children diagnosed with AD.

Từ khóa


Tài liệu tham khảo

10.1172/JCI21060

10.1111/j.1365-2222.2004.01841.x

Marseglia L, 2015, Atopic dermatitis: melatonin as potential treatment, J Biol Regul Homeost Agents, 29, 142

10.1111/j.1398-9995.2006.01153.x

10.1542/peds.2014-0376

10.1016/j.jaad.2007.10.010

10.1016/j.jaci.2006.04.038

10.1016/j.smrv.2010.01.004

10.1056/NEJM199701163360306

10.1007/s00018-014-1579-2

Schwarz W, 1988, Alterations of melatonin secretion in atopic eczema, Acta Derm Venereol, 68, 224

10.1001/jamapediatrics.2015.3092

Kilanczyk E, 2003, The effect of melatonin on antioxidant enzymes in human diabetic skin fibroblasts, Cell Mol Biol Lett, 8, 333

10.1111/j.1600-079X.2005.00273.x

10.1016/j.clnu.2017.12.004

10.1016/j.jphotobiol.2009.11.014

10.1111/jpi.12168

10.1111/jpi.12012

10.3390/ijms150813482

10.1111/j.1468-3083.2006.01664.x

10.1159/000247298

10.1159/000323308

10.1111/sbr.12114

10.1016/j.acthis.2004.10.001

10.1111/j.1600-079X.2009.00718.x

10.1111/bjd.12396

10.1111/cea.12979

Vekaria AS, 2017, Moderate‐to‐severe atopic dermatitis patients show increases in serum C‐reactive protein levels, correlating with skin disease activity, F1000Res, 6, 1712

10.1016/j.jid.2016.08.022

10.4103/2277-9175.204593

10.4103/2277-9175.194801

Mesri Alamdari N, 2015, A double‐blind, placebo‐controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women, Horm Metab Res, 47, 504

10.1111/j.1600-079X.2009.00699.x

10.1016/j.bcp.2010.07.041

10.1038/nrn1950

10.1111/1346-8138.12317

10.1111/j.1365-4632.2009.03906.x

10.1016/j.aller.2016.08.014

10.1007/BF00626365

10.3390/ijms17040462

10.1016/j.smrv.2004.11.004

10.1016/j.smrv.2004.06.004

Buscemi N, 2004, Melatonin for treatment of sleep disorders, Evid Rep Technol Assess (Summ), 108, 1

10.1097/01.chi.0000085756.71002.86

10.1016/j.jaci.2005.09.041

Thông tin
Thông tin xuất bản

Pediatric Allergy and Immunology

Tập 29 Số 8

834-840

Thông tin tác giả